Hepatitis
Hepatitis 03/02/2012
Idenix announces removal of the partial clinical hold on HCV nucleotide inhibitor, IDX184
The Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin may continue.
Hepatitis 01/02/2012
Stem cells could drive hepatitis research forward
By creating liver-like cells, scientists can study why people respond differently to the disease.
Hepatitis 01/02/2012
Aethlon Medical reports immediate and rapid virologic responses in hepatitis C patients receiving Hemopurifier® treatment protocol
The administration of Hemopurifier® therapy during the first three days of standard of care peginterferon+ribavirin drug therapy has demonstrated both immediate and rapid virologic responses in genotype-1 infected HCV patients.
Hepatitis 01/02/2012
European study does not see rapid long-term liver fibrosis in HIV/HCV coinfected people
People who are already HIV positive when they acquire hepatitis C virus may not experience unusually rapid liver disease progression over the long term, even though the fibrosis progression rate may appear high during the acute stage of infection.
Hepatitis 31/01/2012
Cell permeable peptide identified that inhibits hepititis C replication
Discovery could lead to a new treatment for a disease that impacts up to 160 million people worldwide.
Hepatitis 30/01/2012
Alcohol treatment boosts hep C cure rates among drinkers
People who drink—even heavily—can successfully undergo treatment for hepatitis C virus if they’re provided with individualized, multidisciplinary care that also addresses their alcohol use.
Hepatitis 29/01/2012
Statins may stave off liver cancer in people with Hepatitis B
Study found lower risk of developing disease for people taking these cholesterol-cutting drugs.
Hepatitis 29/01/2012
UK: Hepatitis C warning for HIV-positive men
A new report is calling for raised awareness of the risks posed by hepatitis C to gay men living with HIV.
Hepatitis 25/01/2012
Entry point for hepatitis C infection identified
A molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also allows the entry of hepatitis C virus.
Hepatitis 20/01/2012
Vitamin D can inhibit hepatitis C
A new study has found that vitamin D can help to prevent the development of hepatitis C.
Hepatitis 20/01/2012
Common side-effects of hepatitis C protease inhibitors: clinical management advice published
Side-effects can affect adherence to therapy or lead to its premature discontinuation. An understanding of their severity and management is essential to the optimum management of patients taking hepatitis C therapy in routine clinical care.
Hepatitis 19/01/2012
First hepatitis C treatment data demonstrating proof of principle with direct-acting antiviral-only therapy published
Study also demonstrated 100% sustained virologic response 12-weeks post treatment with quadruple therapy.
Hepatitis 17/01/2012
New way to block HCV infection in liver
Researchers developed an inhibitor that decreases the size of host fat droplets in liver cells and stops HCV from taking residence.
Hepatitis 16/01/2012
German review panel sees added benefit for J&J hepatitis C drug
German review panel ruling a key factor in setting the price of new drugs in the German system.
Hepatitis 13/01/2012
Idenix seeks partner for hepatitis C combination drug, CEO Renaud says
The development of drug cocktails for HIV "is a very good road map for what could happen in hepatitis C." HIV treatment involves a "combination of compounds with different mechanisms of action and compensating resistance profiles that beat the disease."
Hepatitis 12/01/2012
Merck hepatitis C drug may ‘anchor' future worldwide regimen
Merck & Co. will make whatever deals are necessary to ensure the company leads the race for future hepatitis C combination therapies.
Hepatitis 11/01/2012
France: Is more frequent monitoring for liver cancer among co-infected people needed?
More frequent monitoring of HIV-HCV co-infected people at high risk for liver cancer may be deemed necessary.
Hepatitis 10/01/2012
Hep C takeover speculation rains down on Idenix and Achillion
Three independent hepatitis C drug developers bought, two more -- Idenix Pharmaceuticals and Achillion Pharmaceuticals -- waiting at the altar.
Hepatitis 10/01/2012
Achillion reports clinical data on portfolio of protease inhibitors
Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatment; Pilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reduction; ACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63 log10 reduction; Additional dosing on-going.
Hepatitis 10/01/2012
Presidio Pharmaceuticals completes PPI-668 Phase 1a study on hepatitis C
PPI-668 is a potent, pan-genotypic second-generation hepatitis C virus NS5A inhibitor.
More...
